Princess Margaret Cancer Centre
University Health Network
Old Toronto, ON
Filters
Save & Share
Clear Filters
Diagnosis
Treatment History
Accepting patients
CAMMA-1
Phase 1B Clinical Trial Studying the Safety, Activity, and Effectiveness of Cevostamab in Treating People with Relapsed or Refractory Multiple Myeloma
Learn more- Bispecific Antibody
- FCRH5
- Phase 1
Accepting patients
LINKER-MM3
A Trial to Learn How Well Linvoseltamab works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants with Relapsed/Refractory Multiple Myeloma
Learn more- Bispecific Antibody
- BCMA
- Randomization
- Phase 3
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trialsAccepting patients
DREAMM5
Platform Study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)
Learn more- Antibody Drug Conjugate (ADC)
- Gamma-Secretase Inhibitor
- BCMA
- Phase 2
- Has results
Not yet accepting
CARTITUDE-6
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)
Learn more- Autologous Stem Cell Transplant
- CAR T Cell
- BCMA
- Phase 3
Not currently accepting
Cevostamab
Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Learn more- Bispecific Antibody
- FCRH5
- Phase 1
- Has results
Accepting patients
BGB-11417
A Phase 1b/2 Study of BGB-11417 in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma
Learn more- BCL-2 Inhibitor
- Phase 1/2
- Has results
Accepting patients
MMSET Inhibitor
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Learn more- Phase 1